Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
VEGFA165 gene therapy ameliorates blood-labyrinth barrier breakdown and hearing loss
Jinhui Zhang, Zhiqiang Hou, Xiaohan Wang, Han Jiang, Lingling Neng, Yunpei Zhang, Qing Yu, George Burwood, Junha Song, Manfred Auer, Anders Fridberger, Michael Hoa, Xiaorui Shi
Jinhui Zhang, Zhiqiang Hou, Xiaohan Wang, Han Jiang, Lingling Neng, Yunpei Zhang, Qing Yu, George Burwood, Junha Song, Manfred Auer, Anders Fridberger, Michael Hoa, Xiaorui Shi
View: Text | PDF
Research Article Angiogenesis

VEGFA165 gene therapy ameliorates blood-labyrinth barrier breakdown and hearing loss

  • Text
  • PDF
Abstract

Millions of people are affected by hearing loss. Hearing loss is frequently caused by noise or aging and often associated with loss of pericytes. Pericytes populate the small vessels in the adult cochlea. However, their role in different types of hearing loss is largely unknown. Using an inducible and conditional pericyte depletion mouse model and noise-exposed mouse model, we show that loss of pericytes leads to marked changes in vascular structure, in turn leading to vascular degeneration and hearing loss. In vitro, using advanced tissue explants from pericyte fluorescence reporter models combined with exogenous donor pericytes, we show that pericytes, signaled by VEGF isoform A165 (VEGFA165), vigorously drive new vessel growth in both adult and neonatal mouse inner ear tissue. In vivo, the delivery of an adeno-associated virus serotype 1–mediated (AAV1–mediated) VEGFA165 viral vector to pericyte-depleted or noise-exposed animals prevented and regenerated lost pericytes, improved blood supply, and attenuated hearing loss. These studies provide the first clear-cut evidence that pericytes are critical for vascular regeneration, vascular stability, and hearing in adults. The restoration of vascular function in the damaged cochlea, including in noise-exposed animals, suggests that VEGFA165 gene therapy could be a new strategy for ameliorating vascular associated hearing disorders.

Authors

Jinhui Zhang, Zhiqiang Hou, Xiaohan Wang, Han Jiang, Lingling Neng, Yunpei Zhang, Qing Yu, George Burwood, Junha Song, Manfred Auer, Anders Fridberger, Michael Hoa, Xiaorui Shi

×

Figure 2

Loss of pericytes causes hearing loss.

Options: View larger image (or click on image) Download as PowerPoint
Loss of pericytes causes hearing loss.
(A and B) Control iDTR mice recei...
(A and B) Control iDTR mice receiving the same 4 doses of DT as the Pdgfrb-CreERT2/iDTR mice showed no significant hearing threshold change at 1 week and 2 weeks (n = 7, P > 0.05 by repeated measures 1-way ANOVA). (C and D) The depletion of pericytes led to hearing loss at all measured frequencies. The hearing threshold in pericyte-depleted animals was significantly elevated at 1 week after DT injection (n = 6, **P < 0.01, and ****P < 0.0001) and persisted 2 weeks after DT injection (n = 6, **P < 0.01, and ****P < 0.0001 by repeated measures 1-way ANOVA). (E and F) Significant HC loss is seen at the middle and basal turns in the pericyte-depleted animals. (E) Representative high-magnification confocal images from control and pericyte-depleted animals, labeled with antibody for myosin VIIa in the different cochlear regions. (F) Total percentage of inner HC (IHC) and outer HC (OHC) (see arrows in E) loss along the entire length of the cochlea in each group was calculated. The pericyte-depleted group showed significantly more IHC and OHC loss (ncontrol = 3, nPC depleted = 6, **P < 0.01 for apical IHC loss, ***P = 0.001 for middle to base IHC loss, ***P < 0.001 for base to hook IHC loss, **P < 0.01 for apical OHC loss, **P < 0.01 for middle to base OHC loss, and ***P = 0.001 for base to hook OHC loss by unpaired Student’s t test). Scale bars: 30 μm.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts